News articles about Abaxis (NASDAQ:ABAX) have been trending positive on Saturday, according to Accern Sentiment. The research firm scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Abaxis earned a media sentiment score of 0.26 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 46.59543009722 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the headlines that may have effected Accern Sentiment’s analysis:

Abaxis (NASDAQ ABAX) traded up $1.75 during mid-day trading on Friday, reaching $64.59. 314,354 shares of the company’s stock were exchanged, compared to its average volume of 302,886. The firm has a market cap of $1,426.28, a P/E ratio of 59.81, a price-to-earnings-growth ratio of 11.19 and a beta of 1.26. Abaxis has a 12 month low of $43.66 and a 12 month high of $78.53.

Abaxis (NASDAQ:ABAX) last released its quarterly earnings data on Thursday, January 25th. The medical research company reported $0.31 EPS for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.05. The company had revenue of $59.70 million during the quarter, compared to the consensus estimate of $59.37 million. Abaxis had a net margin of 10.51% and a return on equity of 10.09%. Abaxis’s quarterly revenue was up 13.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.30 EPS. analysts predict that Abaxis will post 1.16 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 15th. Shareholders of record on Thursday, March 1st will be issued a $0.16 dividend. The ex-dividend date is Wednesday, February 28th. This represents a $0.64 dividend on an annualized basis and a yield of 0.99%. Abaxis’s payout ratio is 59.26%.

Abaxis announced that its board has approved a share buyback plan on Tuesday, October 24th that allows the company to repurchase $21.00 million in shares. This repurchase authorization allows the medical research company to buy shares of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its shares are undervalued.

ABAX has been the topic of a number of research reports. Bank of America decreased their price target on shares of Abaxis from $42.00 to $39.00 and set an “underperform” rating on the stock in a research note on Wednesday, October 25th. Zacks Investment Research lowered shares of Abaxis from a “hold” rating to a “sell” rating in a research note on Thursday, October 26th. Canaccord Genuity reaffirmed a “hold” rating and issued a $47.00 price target (up from $46.00) on shares of Abaxis in a research note on Friday, October 27th. TheStreet raised shares of Abaxis from a “c+” rating to a “b-” rating in a research note on Wednesday, November 29th. Finally, Aegis reaffirmed a “hold” rating on shares of Abaxis in a research note on Friday, December 1st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and one has given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $62.30.

In other Abaxis news, Director Prithipal Singh sold 2,000 shares of the stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $74.63, for a total value of $149,260.00. Following the completion of the sale, the director now owns 44,000 shares in the company, valued at approximately $3,283,720. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Craig Tockman sold 1,650 shares of the stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $74.33, for a total transaction of $122,644.50. Following the completion of the sale, the vice president now owns 10,866 shares of the company’s stock, valued at approximately $807,669.78. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This news story was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at

About Abaxis

Abaxis, Inc is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force.

Insider Buying and Selling by Quarter for Abaxis (NASDAQ:ABAX)

Receive News & Ratings for Abaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abaxis and related companies with's FREE daily email newsletter.